Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363673 | 1.00 | ACE (0.58) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL8216927 | 1.00 | ACE (0.58) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6253538 | 0.91 | ACE (0.49) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL2633846 | 0.89 | ACE (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL7070376 | 0.85 | TGFBR1 (0.52) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL6009831 | 0.85 | TGFBR1 (0.52) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL8491732 | 0.80 | OR51E2 (0.44) | ACEFOLH1OR51E2MMETGFBR1 | |
| SCHEMBL29837094 | 0.80 | OR51E2 (0.44) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL28806122 | 0.80 | OR51E2 (0.44) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL8491734 | 0.80 | OR51E2 (0.44) | ACEFOLH1OR51E2MMETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377099-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | ImmunoVaccine Technologies Inc. (CA) | 2018-09-26 | — | — | EP | claimed |
| CN-108430505-A | The auxiliary system of adjuvant including polyinosinic acid polynucleotides adjuvant and based on lipid and anhydrous vaccine composition | 免疫疫苗技术有限公司 | 2018-08-21 | — | — | CN | claimed |
| WO-2012078116-A1 | IMMUNOGENIC CHIKUNGUNYA VIRUS PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-06-14 | — | — | WO | claimed |
| EP-4144368-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3527224-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-12139512-B2 | Pre-fusion RSV F antigens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| EP-4183412-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-01 | — | — | US | disclosed |
| WO-2001036488-A1 | ANTIBODY AGAINST THE HUMAN TOLL-LIKE RECEPTOR-2 (TLR2) AND USES THEREOF | LEIV EIRIKSSON NYFOTEK AS (NO) | 2001-05-25 | — | — | WO | disclosed |
| US-6074650-A | INDUCTION OF CYTOTOXIC LYMPHOCYTES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| US-6024964-A | ANTIBODIES AND ANTIGENS WITH MEMBRANE ANCHORING | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0210412-B1 | Anchoring membrane ingredient conjugate, and its use | HOECHST AG (DE) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995005454-A1 | ENGINEERED BACTERIOPHAGES AND VACCINES CONTAINING THEM | CAMBRIDGE BACTERIOPHAGE TECHNOLOGIES LTD. (GB) | 1995-02-23 | — | — | WO | disclosed |
| EP-0114787-B1 | PEPTIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-09-25 | — | — | EP | disclosed |
| EP-0210412-A2 | Anchoring membrane ingredient conjugate, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-02-04 | — | — | EP | disclosed |
| EP-0114787-A2 | Peptide derivatives | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | ACE 754/4885KDM4E 4596/4885MAPT 1260/4885 |
| US-12139512-B2 | Pre-fusion RSV F antigens | FURIN, CD69, LY96 | ACE 754/4885KDM4E 4596/4885MAPT 1260/4885 |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | ACE 1308/4885KDM4E 4652/4885MAPT 2978/4885 |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | ACE 754/4885KDM4E 4596/4885MAPT 1260/4885 |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | ACE 1093/4885KDM4E 4397/4885MAPT 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.